Diabetic macular edema (DME)

Diabetic macular edema (DME)

Diabetic macular edema (DME) occurs when the blood vessels in the retina begin to pass diabetes to the macula, the part of the eye responsible for detailed central vision. These leaks cause macular thickening, inflammation, distorted eye slowly. Although inflammation may not lead to blindness, affecting central vision caused serious losses.
Dimethyl ether is an important reason for people with vision loss diabetic retinopathy. People with diabetes have a 10% risk of developing the disease in their lifetime. Alimera estimated that about 100 million people in the United States and developed DME about 300,000 new cases per year.
The dimethyl ether is divided into two types:
Focus macular edema caused by vascular malformations (mainly microvascular), which often escape.
Diffuse macular edema: retinal telangiectasia caused.

Treatment

The current standard of care treatment laser photocoagulation for DME. Laser photocoagulation is a process in the retina, in the process, the use of laser ablation of vascular leakage or application pattern burns reduce edema. This process has undesirable side effects, including partial loss of peripheral and night vision devices. Therefore, these side effects and the desire to improve the visual effects added retina specialists laser photocoagulation treatment with no FDA approved drug, including injections of corticosteroids and anti-vascular endothelial growth factor (anti-VEGF treatment DME) agents. These therapies are limited by the need for multiple injections to maintain a therapeutic effect.